SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D

Weekly tirzepatide injections in adults with type 2 diabetes and overweight or obesity safely produced a 12.8%-14.7% weight loss after 72 weeks in the SURMOUNT-2 pivotal trial.

Related Keywords

United States ,American ,W Timothy Garvey ,Marlon Pragnell ,Janet Brown ,University Of Alabama At Birmingham ,Americsan Diabetes Association ,Health Care Education ,American Diabetes Association ,Research Science ,Diabetes Research Center ,Drug Administration ,Access Will Remain ,Janet Brown Friday ,Health Care ,Weight Loss ,Diabetes Association ,Obesity ,Bese ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,